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OBJECTIVES The purpose of this study was to determine whether the elevated levels of hemostatic markers
in the early phase of myocardial infarction may serve as risk factors for subsequent cardiac
mortality.
BACKGROUND Increased plasma hemostatic markers were noted in acute myocardial infarction, indicating
that the blood coagulation system is highly activated in those patients. However, there are few
clinical data concerning the association between the elevated hemostatic markers and survival
in patients with myocardial infarction.
METHODS Blood samples were obtained from 64 patients (mean age 67 6 11 years; 49 male) with acute
myocardial infarction within 12 h after the onset of symptoms and before the initiation of any
antithrombotic treatment. We measured plasma concentrations of fibrinopeptide A (FPA),
prothrombin fragment 112 (F112) and thrombin-antithrombin complex (TAT) using the
enzyme-linked immunosorbent assay method, and examined the associations between the
level of these markers and survival with Cox proportional hazards models.
RESULTS The follow-up time was 27 6 17 months, and 19 patients died of cardiac causes during the
follow-up. Univariate survival analysis identified Killip class IV (hazard ratio 4.86; 95%
confidence interval [CI] 1.55–15.19), left ventricular ejection fraction (hazard ratio 0.94; 95%
CI 0.90–0.99), FPA (hazard ratio 1.54; 95% CI 1.13–2.10), F112 (hazard ratio 2.03; 95%
CI 1.17–3.53) and TAT (hazard ratio 1.88; 95% CI 1.27–2.79) as significant factors
associated with cardiac mortality. In multivariate analyses, only FPA level (hazard ratio 1.84;
95% CI 1.03–3.30) and left ventricular ejection fraction (hazard ratio 0.93; 95% CI
0.88–0.98) were independent predictors of cardiac mortality.
CONCLUSIONS Elevated FPA in the early phase of myocardial infarction identifies patients with increased
risk for subsequent cardiac death. This association appears to be independent of residual left
ventricular function after infarction. (J Am Coll Cardiol 1999;33:1543–8) © 1999 by the
American College of Cardiology
Intracoronary thrombus formation is the most important
pathogenetic mechanism in unstable angina and acute
myocardial infarction (1–4). The thrombi can be demon-
strated clearly by angiographic (5,6), angioscopic (7,8) and
histological examinations (9,10) in coronary arteries of these
patients. Thrombotic process involves a chain of reactions
that transform, in sequence, a number of coagulation factors
present as precursors in plasma into an activated form, and
lead to thrombin generation with subsequent fibrin and clot
formation. Several highly sensitive and specific hemostatic
markers have been developed that can monitor the activities
of coagulation system in vivo. The most extensively studied
hemostatic markers are fibrinopeptide A (FPA) (11,12) and
prothrombin fragment 112 (F112) (13,14). FPA is the
polypeptide cleaved from fibrinogen by thrombin, and
hence a sensitive marker of thrombin activity and early
fibrin formation. F112 is released from the amino-terminal
end of prothrombin during thrombin generation and it
indicates the activity of factor Xa. Many studies have
demonstrated that coagulation system is highly activated in
the acute phase of unstable angina and myocardial infarction
(15–17). The plasma levels of FPA and F112 were signif-
icantly elevated in patients with acute coronary syndromes
when compared with those with stable angina (15–17).
Thrombin is neutralized by its physiological inhibitor anti-
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thrombin III. The thrombin-antithrombin complex (TAT)
is another important procoagulant marker. It was also found
to be increased in patients with acute myocardial infarction
(18). Although coagulation activation with thrombosis for-
mation is important in the pathogenesis of acute coronary
syndromes, there are few studies concerning the influence of
hemostatic function on clinical outcomes in these patients.
Previous studies showed that increased plasma FPA could
predict in-hospital adverse cardiac events after the attack of
unstable angina or myocardial infarction (18,19). However,
it is unknown whether these hemostatic markers may
predict the long-term outcome in patients with acute
coronary syndromes. Therefore, in this study, we measured
the plasma hemostatic markers in patients suffering from
acute myocardial infarction and evaluated their usefulness in
predicting the survival of these patients.
METHODS
Study population. Seventy consecutive patients admitted
to the National Cheng Kung University Hospital with the
diagnosis of acute myocardial infarction from January 1993
to March 1994 were included in this study. Among them,
six were excluded because we were unable to obtain current
information regarding these patients. The remaining 64
patients (mean age 67 years; range 29 to 88 years) form the
basis of this study. The diagnosis of acute myocardial
infarction was based on a history of prolonged ischemic
chest pain, characteristic electrocardiographic changes and
elevation of cardiac enzymes. Blood samples for hemostatic
markers measurement (FPA, F112, TAT) were obtained
immediately from these patients in the emergency room or
coronary care unit within 12 h after the onset of symptoms
and before the initiation of any thrombolytic or anticoagu-
lant treatment. After admission, all patients received regular
medical treatment for myocardial infarction, including an-
giotensin converting enzyme inhibitor or beta-adrenergic
blocking agent as indicated, and 53 of them received
intravenous thrombolytic therapy. Revascularization proce-
dures were performed on 16 patients either by percutaneous
transluminal coronary angioplasty (n 5 13) or coronary
graft bypass surgery (n 5 3) at a mean time of 12 days after
the onset of myocardial infarction. According to the elec-
trocardiographic criteria, the site of infarction was anterior
in 37 patients, inferior in 25 patients and at other locations
in 2 patients. Killip classification (20) based on physical
findings during admission was determined in each patient as
a prognostic guide. The left ventricular ejection fraction was
measured using the Teichholz formula (21) from trans-
thoracic echocardiography. No patient had a previous drug
history of warfarin. There were also no histories of hemo-
static disorders, malignancies or chronic inflammatory dis-
eases in these patients. The mean follow-up period was
27 6 17 months, ranging from 1 day to 53 months. The
survival of each patient was assessed either to the day of
death or to July 31, 1997. Follow-up data of these patients
were obtained from detailed chart review and contact with
patients or their families if necessary. The study protocol
was approved by the Institutional Research Committee of
our hospital.
Sample preparation. Blood samples were collected with
the two-syringe technique by clean, flawless venipuncture
using a 20-gauge needle. After the first 3 mL was discarded,
the blood for FPA measurement was collected in a tube
with special anticoagulant solution containing citrate, hep-
arin and specific protease inhibitor. The ratio of anticoag-
ulant to blood was 1:9 (vol/vol). All samples were stored in
ice and immediately centrifuged at 4°C for 10 min at
1,500 g. The supernatant plasma was collected and treated
with bentonite to remove fibrinogen, and then the plasma
was frozen at 270°C until use. FPA was measured by
commercial enzyme-linked immunoassay kits (Diagnostica
Stago, Asnieres sur Seine, France) within one month after
collection. The value was expressed as ng/mL. For F112
and TAT measurement, 9 mL venous blood was mixed
carefully with 1 mL sodium citrate solution (0.11 mol/liter).
The samples were immediately centrifuged at 4°C for
10 min at 1,500 g. The supernatant plasma was collected
and immediately frozen at 270°C until use. Commercial
enzyme-linked immunoassay kits (Diagnostica Stago,
France) were used to measure F112. TAT was also mea-
sured by similar commercial enzyme-linked immunoassay
kits (Behringwerke, Marburg, Germany). The values were
expressed as nmol/L for F112 and ng/mL for TAT. The
normal ranges of these hemostatic markers in our laboratory
from 16 healthy control subjects matched for age and sex
with the cardiac patients were: 4.3 6 0.3 ng/mL for FPA,
0.9 6 0.1 nmol/liter for F112 and 1.5 6 0.3 ng/mL for
TAT.
Statistical analysis. The clinical characteristics and levels
of hemostatic markers were compared between patients
with and without cardiac mortality. In comparing clinical
characteristics between the groups, the chi-square test was
used to evaluate the differences in categoric variables, and
the Student t test was used to test the differences in
continuous variables. As plasma levels of hemostatic mark-
ers were nonnormally distributed, the Wilcoxon rank sum
test was used to evaluate the differences in these variables.
The Pearson correlation analysis was used to assess the
relations of plasma level of each hemostatic marker with
patient’s age, maximal creatine kinase and left ventricular
ejection fraction. Survival analyses were conducted using the
Cox proportional hazards models. Univariate analysis was
used to examine correlations between clinical characteristics
Abbreviations and Acronyms
FPA 5 fibrinopeptide A
F112 5 prothrombin fragment 112
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(age, gender, hypertension, diabetes, smoking, cholesterol,
previous infarction, Killip classification, thrombolytic ther-
apy, revascularization procedure and maximal creatine ki-
nase level) as well as hemostatic markers and survival after
myocardial infarction. The data for hemostatic markers
were analyzed in a logarithmic scale to reduce the skew in
the data. Multivariate Cox proportional hazards models
were used to assess the relation between hemostatic markers
and other clinical variables. Each hemostatic marker was
evaluated in a model that included the clinical characteristics
that appeared to be statistically significant predictors of
survival. Survival curves were constructed according to the
method of Kaplan and Meier (22). In constructing the
curves, each hemostatic marker was dichotomized to pro-
vide approximately equal numbers of deaths in the two
comparison groups. All data were expressed as mean 6 SE.
A p value ,0.05 was considered statistically significant. The
statistical analyses were carried out using SAS for Windows
Version 6.11.
RESULTS
During the follow-up period, 19 patients died due to cardiac
causes, and 45 patients were alive at the end of this study.
Seven patients died of sudden cardiac death, five patients
died of cardiogenic shock, five patients died of refractory
heart failure and two patients died of cardiac free-wall
rupture. The clinical characteristics, follow-up periods and
causes of death are shown in Table 1. These patients died
from 1 day to 25 months after onset of acute myocardial
infarction. The cardiac mortality was spread evenly over the
duration of follow-up and was not found to be concentrated
shortly after myocardial infarction. Table 2 shows the
baseline clinical characteristics and hemostatic markers in
patients with or without cardiac mortality. There were no
significant differences in the coronary risk factors, sites of
infarction, previous infarctions and modalities of treatment
(thrombolytic therapy or revascularization procedures) be-
tween the patients who survived and died. The patients who
died subsequently due to cardiovascular causes had higher
percentages of Killip class IV and lower left ventricular
ejection fractions. The initial levels of the three hemostatic
markers (FPA, F112 and TAT) were also significantly
higher in these patients. When patients were grouped
according to the site of infarction, we found no statistically
significant differences of hemostatic marker level in FPA
(8.1 6 2.1 vs. 7.2 6 2.4; p 5 NS), F112 (4.0 6 0.7 vs.
5.4 6 0.9; p 5 NS) or TAT (13.9 6 3.5 vs. 19.3 6 4.4; p 5
NS) between those with anterior and inferior myocardial
infarction. There were also no significant correlations of
plasma FPA, F112 or TAT with patient’s age (r 5 0.17,
20.01, 20.10), maximal creatine kinase (r 5 20.09, 0.02,
0.02) and left ventricular ejection fraction (r 5 0.13, 0.05,
20.09; all p 5 NS).
Table 3 summarizes the associations of clinical charac-
teristics and hemostatic markers with survival after myocar-
dial infarction. Using univariate Cox proportional hazards
models, we found that Killip class IV, left ventricular
ejection fraction and logs of each of the three hemostatic
markers were significantly associated with patient mortality
(Table 3). The influence of elevated hemostatic markers on
survival is illustrated in Figure 1. In Kaplan-Meier survival
analyses, the hemostatic marker levels were dichotomized to
provide an approximately equal number of deaths in the two
groups. The groups with elevated hemostatic markers on
admission showed significantly higher mortality rates (Fig.
1). Furthermore, according to multivariate Cox proportional
hazards models, log (FPA) level (hazard ratio 1.84; 95%
confidence interval [CI] 1.03–3.30; p 5 0.04) and left
ventricular ejection fraction (hazard ratio 0.93; 95% CI
0.88–0.98; p 5 0.006) were the only independent predic-
tors of cardiac mortality. This indicates that the initial FPA
level may provide prognostic significance independent of
usual clinical characteristics including left ventricular func-
tion after myocardial infarction.
DISCUSSION
Several recent studies have shown that elevated plasma
levels of hemostatic markers are associated with increased
risk of early adverse cardiac events in patients with acute
coronary syndromes (18,19). In current study, we found that
the initial plasma levels of FPA, F112 and TAT are good
Table 1. Clinical Characteristics, Follow-up Periods and Causes
of Death in Patients With Cardiac Mortality
Age
(yr)
Gender
Infarction
Site
Peak
CK
(U/L)
Follow-up
Period Cause of Death
75/M inferior 2390 1 d cardiogenic shock
62/F anterior 1551 2 d sudden cardiac death
56/F anterior 1342 3 d cardiogenic shock
66/M inferior 3224 4 d cardiogenic shock
69/M inferior 3084 4 d cardiac rupture
69/M anterior 913 10 d cardiogenic shock
85/M anterior 1683 13 d refractory CHF
75/F anterior 2360 1 mo reinfarction with
cardiac rupture
68/M inferior 3141 1 mo sudden cardiac death
with VF
52/M anterior 2576 1 mo refractory CHF
61/M inferior 2957 3 mo angina with VF
74/F anterior 1639 4 mo sudden cardiac death
with VF
73/M anterior 4454 4 mo refractory CHF
76/F inferior 3437 12 mo sudden cardiac death
74/M inferior 3430 14 mo reinfarction with
cardiogenic shock
71/M anterior 2915 17 mo refractory CHF
79/F anterior 668 20 mo sudden cardiac death
81/M inferior 1906 22 mo reinfarction with CHF
64/F inferior 5365 25 mo sudden cardiac death
CHF 5 congestive heart failure; VF 5 ventricular fibrillation.
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predictors of mortality not only in the acute phase of
myocardial infarction but also in the long-term outcome.
Moreover, the correlation between FPA and survival after
myocardial infarction is independent of the residual left
ventricular function. Thus, FPA appears to provide addi-
tional information on prognosis after myocardial infarction.
Prognostic value of hemostatic marker. Ardissino et al.
(19) first demonstrated that patients with increased levels of
FPA had a significantly higher probability to develop
cardiac events during hospitalization. The independent
variables predicting early unfavorable outcome in these
patients were the presence of persistent ischemia on 24-h
Holter monitoring, the presence of intracoronary thrombo-
sis at angiography and abnormal plasma FPA level. The
results of this study clearly demonstrated the close associa-
tion between the activation of coagulation and adverse
clinical outcome. Recently, the data from the Thrombolysis
in Myocardial Infarction (TIMI)-5 Study (18) also suggest
that hemostatic markers may be useful in predicting short-
term clinical outcome in patients with acute myocardial
infarction treated with thrombolytic therapy. They found
that increased levels of FPA and TAT at 1 h after
thrombolytic therapy were associated with higher in-
hospital mortality. In our study, increased levels of hemo-
static markers, especially FPA, in the acute phase of
myocardial infarction were strongly associated with subse-
quent cardiovascular mortality. The cardiac death was
spread evenly over the duration of follow-up and not
concentrated shortly after myocardial infarction. Our study
is the first one to suggest that elevated hemostatic markers
in the early stage of myocardial infarction not only links to
immediate death during hospitalization but also predicts a
poor long-term prognosis in these patients. The correlation
between FPA and survival was also independent of residual
left ventricular systolic function after myocardial infarction.
Our data may have important clinical potential because
plasma level of FPA is easily measured in clinical laborato-
ries, and this noninvasive marker may provide additional
prognostic information regarding subsequent risk of death
in acute myocardial infarction patients.
Mechanisms of hemostatic markers as prognostic indi-
cators. It is still uncertain about the definite underlying
mechanisms for the association between elevated hemostatic
markers and adverse clinical outcome in acute coronary
syndromes. The increased coagulation activation markers in
these patients reflect an active intracoronary thrombotic
process. Wilensky et al. (23) used angiographic features to
grade the probability of intracoronary thrombus formation
from 0 (no thrombus) to 4 (definite thrombus) in patients
with unstable angina. They found that FPA levels correlated
significantly with the presence of grade 3 or 4 intracoronary
thrombus. Thrombosis formation in coronary arteries re-
sults from the rupture or fissuring of atherosclerotic plaques
and exposure of procoagulant subendothelial surface to
blood. However, the factors that determine the thrombus
burden have not been well defined. In studying patients
with unstable angina, Eisenberg et al. (24) found that
Table 3. Univariate Relations of Clinical Characteristics and
Hemostatic Markers With Survival After Myocardial Infarction
According to Cox Proportional Hazards Models
Variables
Hazard Ratio
(95% CI)
p
Value
Age (yrs) 1.03 (0.98–1.08) 0.20
Male 0.42 (0.16–1.07) 0.07
Hypertension 1.47 (0.58–3.72) 0.42
Diabetes 1.43 (0.51–3.97) 0.49
Smoking 0.40 (0.25–1.01) 0.06
Cholesterol (mg/dl) 0.99 (0.98–1.01) 0.32
Thrombolytic therapy 0.55 (0.20–1.53) 0.25
Revascularization 0.31 (0.07–1.37) 0.12
Anterior MI 1.47 (0.60–3.63) 0.99
Previous MI 0.68 (0.16–2.96) 0.61
Maximal CK (U/l) 1.00 (1.00–1.00) 0.97
Killip class IV 4.86 (1.55–15.19) 0.007
Left ventricular EF (%) 0.94 (0.90–0.99) 0.01
log (FPA) 1.54 (1.13–2.10) 0.006
log (F112) 2.03 (1.17–3.53) 0.01
log (TAT) 1.88 (1.27–2.79) 0.002
Abbreviations as in Table 2.
Table 2. Comparison of Clinical Characteristics and Hemostatic
Markers Between Patients With and Without Cardiac Death
Cardiac Death
p
Value
No
(n 5 45)
Yes
(n 5 19)
Clinical characteristics:
Age (yrs) 65.7 6 1.8 70.0 6 1.9 NS
Male 37 (82%) 12 (63%) NS
Hypertension 23 (51%) 12 (63%) NS
Diabetes 9 (20%) 5 (26%) NS
Smoking 36 (80%) 11 (58%) NS
Cholesterol (mg/dl) 195.6 6 7.0 183.9 6 11.5 NS
Thrombolytic therapy 39 (87%) 14 (74%) NS
Revascularization 14 (31%) 2 (11%) NS
Anterior MI 27 (60%) 10 (53%) NS
Previous MI 7 (16%) 2 (11%) NS
Maximal CK
(U/liter)
2581.8 6 313.7 2,593.1 6 286.8 NS
Medication 28 (62%) 8 (42%) NS
Killip class IV 2 (4%) 6 (32%) , 0.01
Left ventricular
EF (%)
55.4 6 2.3 42.2 6 3.2 , 0.01
Hemostatic markers:
FPA (ng/ml) 3.9 6 1.2 13.1 6 3.1 , 0.01
F112 (nmol/liter) 3.7 6 0.5 6.7 6 1.2 , 0.01
TAT (ng/ml) 11.2 6 2.6 27.3 6 5.7 , 0.01
CK 5 creatine kinase; EF 5 ejection fraction; FPA 5 fibrinopeptide A; F112 5
prothrombin fragment 112; Medication 5 Beta blocker or angiotensin-converting
enzyme inhibitor; MI 5 myocardial infarction; TAT 5 thrombin-antithrombin
complex. Data are presented as mean 6 SE or number (%) of patients with the
condition.
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plasma concentrations of FPA were markedly elevated in
64% of patients with complex coronary lesions noted on
angiographic examinations. This result demonstrated that
increased thrombin activity indicated by increased concen-
trations of FPA might reflect the intrinsic procoagulant
properties of the coronary atherosclerotic lesions. These
kinds of complex coronary lesions may evoke recurrent
ischemic events during the follow-up period and influence
the prognosis of these patients. Another possible reason that
increased hemostatic markers may affect prognosis is the
duration of coagulation activation in patients with acute
coronary syndromes. Merlini et al. (25) have shown that, in
patients with unstable angina and myocardial infarction,
plasma levels of F112 were elevated during the occurrence
of the acute episodes and remained high even after 6 months
of uneventful clinical course. It seems that, after the attack
of acute coronary syndromes, there is a sustained hyperco-
agulability state in some patients. Hypercoagulability state
creates a thrombogenic milieu, which may be related to the
occurrence of subsequent thrombus formation with recur-
rent ischemic events. Thus, in the acute stage of myocardial
infarction, increased hemostatic markers probably not only
represent increased intracoronary thrombus formation but
also mean more complicated and thrombogenic coronary
lesions, and a more sustained hypercoagulable state. All
these factors may influence the late prognosis.
Study limitations. One of the major limitations of this
study is the relatively small number of enrolled patients.
Previously reported poor prognostic indicators of myocar-
dial infarction, such as diabetes mellitus, were found to be
associated with poor survival in our study, but the increase
in risk was not statistically significant. This association
needs to be confirmed by further studies with larger num-
bers of patients. Nonetheless, the power of this study was
large enough to detect the differences in the FPA level and
the left ventricular ejection fraction between patients with
and without cardiac death even in the multivariate analyses.
Furthermore, we observed a relatively high mortality rate
(30%) in our study population. Because our hospital is the
major teaching hospital in the region, it becomes the final
destination of referral for many severe patients. Therefore,
our study cohort may not be representative of patients with
acute myocardial infarction in the general population. How-
ever, selection bias, which occurs in a cohort study when
knowledge of outcome (cardiac death in our study) is used
in defining study groups (26), could not appear in our study
because the clinical outcome was not known at the time of
recruiting study participants. We did not assess the effects of
drug treatment, including angiotensin-converting enzyme
inhibitor and beta-blocker, on survival after myocardial
infarction in this study. In fact, there were no differences
between the participants with and without cardiac death in
terms of the proportion of patients being given these drugs.
Therefore, these medications should have no significant
influences on the results of this study. Various revascular-
ization procedures, including percutaneous transluminal
coronary angioplasty and coronary graft bypass surgery, were
used in patients with myocardial infarction in this study.
They may affect the prognosis. Likewise, since there was
also no significant difference in the proportion of patients
receiving these procedures between the two groups of
patients, these procedures could not have biased our study
results.
Conclusions. In this study, we demonstrate that hemo-
static markers measured in the early stage of acute myocar-
dial infarction are correlated with subsequent cardiac mor-
Figure 1. Kaplan-Meier curves of mortality under a dichotomy of
hemostatic marker levels. The dichotomy was chosen to provide an
equal number of deaths in the two comparison groups. Top, FPA;
middle, F112; and bottom, TAT.
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tality in our patients, and the correlation of FPA with
survival is independent of the residual left ventricular
function after myocardial infarction. Because elevated he-
mostatic markers identify patients with myocardial infarc-
tion at increased risk of death, they have clinical potential to
be used as prognostic indicators in risk stratification after
acute myocardial infarction.
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